I finally got to sit down and read the BETonMACE JAMA paper and editorial. Both well written. However, nothing new caught my eye that we didn't already know from AHA or the post-AHA company webcast. Nothing on the CKD sub-study other than showing the MACE data. But we already know this. There was a more comprehensive plasma clinical chemistry panel in the JAMA paper, but no changes stood out between the placebo and apabetalone groups. No emphasis in the paper on the MACE benefit in pre-specified subgroups (eGFR, LDL-C, SGLT2 and/or GLP1R agonist).
Epigenetic Therapeutics for Cardiovascular Disease
Writing, Erasing, Reading, and Maybe Forgetting
https//jamanetwork.com/journals/jama/fullarticle/2763949
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes
A Randomized Clinical Trial
